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ABSTRACT 
Acute administration of haloperidol to rats causes a marked de-
crease in the Km of neostriatal tyrosine hydroxYlase for the pteri-
dine cofactor, 6MPH 4 , with no change in Vrnaxo This effect is de-
pendent on the pH of the assay mixture. It occurs at pH 6.5 but 
not at pH 6.0, the pH optimum for THo With phosphorylating con-
ditions at pH 6.5, the haloperidol-induced activation is no longer 
observed, and the kinetics of TH are the same as those from control 
rats. At pH values of 600, 6.3 and 6~5, a significant decrease in 
Vmax occurs, with increasing pH, while no significant change in 
Km for the cofactor is observed for TH from control ratso However, 
when phosphorylating conditions are employed, a marked increase in 
~ for the cofactor is observed while only a slight decrease in Vmax 
is seen, with increasing pH, for the control enzyme at the three pH 
values tested. 
The kinetic characteristics of neostriatal tyrosine hydroxylase 
(TH) activity were then determined after rats were given large, re-
peated doses of methamphetamine. The Vmax of the enzyme was 
markedly decreased after methamphetamine, but no change in the Km 
for pteridine cofactors nor for the substrate, tyrosine, was de-
tectedo The decrease in Vmax with methamphetamine was independent 
of the phosphorylated state of the enzyme. 
The effect of propranolol in blocking the methamphetamine-
induced depression of tryptophan hydroxylase was then investigated. 
Acute administration of methamphetamine produced a marked decrease 
in tryptophan hydroxylase activity in all serotonergic nerve ter-
minal regions of rat brain examined. This decrease was antagonized 
1n a regionally selective manner by propranolol. Almost complete 
blockade occurred in regions that are commonly implicated in schizo-
phrenia, mesolimbic areas, neostriatum, and hypothalamus; whereas 
in other regions examined, only partial or no blockade occurred. 
In contrast, haloperidol did not produce a similar antagonism. The 
results are discussed in the context of the efficacy of large doses 
of propranolol in some schizophrenic patients. 
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This thesis is comprised of three parts that may appear to be 
different but do, in fact, have a common theme: i.e. the effect of 
centrally acting drugs on the activity of enzymes that are rate-
limiting in the biosynthesis of certain neurotransmitterso This in-
cludes drugs that can induce a schizophrenia-like syndrome as well 
as drugs that are used clinically in the treatment of schizophrenia. 
The first part involves a study of the mechanism by which halo-
peridol, a commonly used antipsychotic drug, produces activation of 
tyrosine hydroxylase, the rate-limiting enzyme in the biosynthesis 
of dopamineo It includes a systematic kinetic study of the inter-
action between the in vitro effect of the hydrogen ion concentration, 
the phosphorylated state of the enzyme and the ~ vivo induction of 
tyrosine hydroxylase activation by haloperidol 0 The relevance of 
this study lies in understanding the mechanisms by which haloperidol 
produces an increase in tyrosine hydroxylase activity which controls 
the synthesis of dopamine. This may provide an insight into the 
clinical effects seen with haloperidol 0 The second part involves a 
kinetic study of the effect of methamphetamine in lowering the activ-
ity of tyrosine hydroxylase, which has been observed with chronic 
treatment. The possibility of a change in the affinity of the enzyme 
for the substrate or the cofactor, as well as alteration in the maxi-
mum velocity of the enzyme, was investigated. In addition, the in-
fluence of the phosphorylated state of the enzyme on the above para-
meters was also examined. Finally, a time-course of kinetic changes 
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in tyrosine hydroxylase activity following chronic treatment of rats 
with methamphetanline was characterized. 
The third and last part attempts to provide a biochemical 
rationale for the efficacy of large doses of propranolol in schizo-
phrenia. An animal model was utilized in which rats were treated 
with methamphetamine to produce stereotyped behaviors that may be a 
correlate of the psychotic state in humans. This behavior in animals 
is associated with a decrease in the activity of tryptophan hydroxy-
lase in different regions of the rat brain. The effect of pro-
pranolol, which has recently been shown to bind the 5-hydroxytrypt-
amine binding sites, in preventing the depression in tryptophan hy-
droxylase activity was investigated and the results were correlated 
with its clinical efficacy. 
PART TWO 
IN VITRO EFFECTS OF pH AND PHOSPHORYLATION ON NEOSTRIATAL TYROSINE 
HYDROXYLASE FROM CONTROL AND HALOPERIDOL-TREATED RATS 
Introduction 
Modulation of the activity of tyrosine hydroxylase (TH), the 
rate-limiting enzyme in catecholamine biosynthesis (1). by hydrogen 
ion concentration and phosphorylating systems has become the focus 
of increasing attention in recent yearso The activity of TH from 
rat brain and adrenal medulla is sensitive to pH (2,3) as well as 
to phosphorylation (3-10). Various antipsychotic drugs also pro-
duce a change in the activity of the enzyme (11,12)0 For example, 
acute doses of haloperidol produce a marked increase in the affinity 
of TH for the pteridine cofactor with no effect on the Km for the 
substrate (11)0 We have recently shown that this effect of haloperi-
dol is pH-dependent (13)0 It occurs at higher pH values but not at 
lower values. It is possib1e,that haloperidol, as well as other 
drugs, may produce their effect by phosphorylation of the enzyme o 
In an attempt to understand the relationship between pH, phosphoryla-
tion and the haloperidol-induced effects on the regulation of TH, we 
have examined the kinetic characteristics of rat neostriata1 TH with 
regard to the pteridine cofactor. 
Methods 
Male Sprague-Dawley rats, weighing 150-250 gm, were housed three 
per cage in a temperature-controlled room (26°) with a 12-hr 1ight-
dark cycle. Food and water were offered ad libitum. Rats were in-
jected with haloperidol (1 mg/kg, i.p.) which was dissolved in 1% 
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lactic acid. Control rats were injected with the lactic acid solu-
tion. Control and treated rats were sacrificed by decapitation one 
hour after injectiono Rat neostriata were rapidly dissected out, 
wrapped in parafilm and placed on dry ice, and then stored at -70°C 
until assayed. 
All steps for preparing the enzyme were performed at 0-5°C and 
TH activity was determined by the method of Nagatsu et a10 (14)0 
The neostriata were homogenized in 008 m1 of 0.2 M sodium acetate 
buffer, containing 0.2% Triton X-100 and centrifuged at 27,000 X g 
for 15 min. at 4°Co The desired pH was adjusted at 37°C with glacial 
acetic acid. The supernatant fractions of neostriata from two rats 
were combined and 50-~1 a1iquots were assayed -in a total volume of 
100 ~1 of incubation medium, containing: 1 mM ferrous ammonium sul-
fate, 100 mM of mercaptoethano1, 0.2 M sodium acetate pH 600, 6.3 
or 605,001 mM tyrosine, 0.4 ~Ci purified 3,5-ditritiotyrosine, and 
varying concentrations of 2-amino-6-hydroxy-6-methy1tetrahydropterin 
(6MPH4 , Ca1biochem). When phosphorylating conditions were employed, 
the incubation mixture (100 ~l) also contained, in addition to the 
above, the following components (expressed as final concentrations): 
12.5 mM of magnesium acetate, 12.5 mM of sodium fluoride, 0.5 mM of 
theophylline, 0.075 w4 of EGTA, 0.312 mM of ATP, and 0.0725 mM of 31 , 
51 -cAMP (5)0 Control samples from the same homogenate were assayed 
under normal and phosphorylating conditions at pH values of 6.0, 6.3 
and 6.5" 
The incubation was carried out at 37°C for 15 min. and termi-
nated by the addition of 100 ~1 of 10% trichloroacetic acid. The 
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acidified incubation medium was then placed on a 005 x 2.0 cm 
Dowex 50-H+ column and washed with 10 8 ml of distilled water. After 
addition of 15 m1 of scintillation fluid, which contained 7.6 g of 
2,5-diphenyloxazol in 1 liter toluene-Triton X-100 (2:1), the tri-
tiated water produced was counted in a Packard liquid scintillation 
countero 
Results 
Neostriatal tyrosine hydroxylase activity from control and halo-
peridol-treated rats was assayed at the following final pH values, 
6.0, 6.3 and 6.5, with and without phosphorylating conditions. Line-
weaver-Burk plots were obtained by varying the concentration of the 
cofactor, 6MPH4 , and measuring the initial velocity of tyrosine oxi-
dizied. The activity of TH may be variably influenced by different 
cofactors and assay systems (15,16). In this study the cofactor 
was held constant and the effects of pH and phosphorylation were 
determinedo As reported previously by other investigators (11), at 
pH 6.5 haloperidol did not change the apparent Vmax but caused a 
marked decrease in the Km of the enzyme for the pteridine cofactor 
(Fig o 1)0 However, when TH activity from control and haloperidol-
treated rats was assayed under phosphorylating conditions at pH 605, 
an increase in Vmax but no change in Km for the enzyme from control 
rats occurredo In the haloperidol-treated rats an increase in Vmax 
and an increase in the Km for 6MPH 4 was observed with phosphorylating 
conditionso This Km was not significantly different from the Km of 
the enzyme from control animalso 
8 
Fig. 1 The effect of phosphorylating condition~ on the apparent Km 
for 6MPH~ and Vmax of neostriatal tyrosine hydroxylase from control 
and haloperidol treated rats at pH 6.5. The velocities are expressed 
in nanomoles of tyrosine oxidized/gm/hr. 
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It should be noted that at pH 6.5 the enzyme activity was 
greatly diminished relative to values obtained at optimum pH con-
ditions (5.7 - 6.0) and the activation produced by phosphorylation in-
creased the Vmax by more than 3-fold, to a value approximating that 
of the nonphosphorylated TH measured at the ~ vitro pH optimum. 
The kinetic parameters for the control and haloperidol-treated 
rat neostriata1 TH at three pH values, with and without phosphoryla-
ting conditions, is presented in Table 1. At pH 6.3, neostriata1 TH 
from haloperidol-treated rats showed no significant activation and 
the Vmax and Km values were not significantly different from control 
values. Furthermore, when the enzyme from the two groups was phos-
phorylated, a similar increase in Vmax and a slight decrease in KID 
occurred in neostriatal TH from both control and haloperidol-treated 
rats. In addition, at pH 6.0, no significant difference was ob-
served in the kinetics of TH.from control and haloperidol-treated 
rats 0 
The kinetics of the phosphorylated enzyme with respect to the 
cofactor were then studied at the pH optimum, 6.0. As reported pre-
viously by other investigators (5-7), we observed a significant de-
crease in Km but no change in Vmax (Table 1). The effects of pH 
variation on the kinetics of the enzyme from control rats assayed 
under normal and phosphorylating conditions were analyzed by compara-
tive Lineweaver-Burk plots (Fig. 2). 
The kinetics of control and control-phosphorylated enzyme dif-
fered markedly. With increasing pH, a shatp decrease in Vmax but 
no significant change in Km was observed for control TH (Fig. 2a). 
Table 1 
Effects of pH and phosphorylation on apparent Km for 6MPH4 and Vmax 






Km* 0.15 ± 00 02 0.15 ± 0.02 0.08 ± 0.005 
pH 6.0 Vmt 2430 ± 168 2499 ± 162 2638 ± 78 
pH 6.3 Km 0.17 ± 0.01 0015 ± 00 02 0.12±0.01 O. 11 ± 0.02 
Vm 1387 ± 165 1151 ± 131 2155 ± 142 2440 ± 60 
pH 6 0 5 Km O'.18±0.01 0.10 ± 0.003 0.17±OoOl 0.18±0.01 
* 
Vm 508 ± 10 522 ± 24 1931 ± 210 2281 ± 110 
The results are expressed as the means ± SEM from at least 
four separate enzyme preparations each of which were ob-
tained from pooled striata from 2 rats and assayed in dupli-
cate. . 
expressed in mM 
expressed in nmo1es tyrosine oxidized/gm/hr 
The kinetic behavior of TH from lactic acid controls were not 
significantly different than saline-injected rats o 
Appropriate comparisons of values in the table were made and 
significance determined by Student1s t-test. When the SEMis 
did not overlap, the values were found to be significant, 
p<O.05. 
11 
Fig. 2 The effect of pH on the apparent Km for" 6MPH4 and Vmax of 
control and phosphorylated neostriatal tyrosine hydroxylase. The 
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With phosphorylating conditions, the Km of the enzyme for the cofactor 
markedly increased, and a slight decrease in the Vmax was observed 
with increasing pH values (Fig. 2a). 
Discussion 
The present studies indicate that the kinetic behavior of tyro-
sine hydroxylase, with respect to the pteridine cofactor, is variably 
influenced by the pH of the assay mixture and the phosphorylated 
state of the enzyme. The affinity of TH for the pteridine cofactor 
is significantly enhanced following acute treatment of rats with 
haloperidol (11)0 This haloperidol-induced effect is, however, de-
pendent on the pH of the assay medium (13), and can only be observed 
at the higher pH range, but not at the in vitro pH optimum for TH, 
6.0. In fact, no significant activation by haloperidol treatment 
was observed at pH 6.3 (Table 1). When mea'sured above pH 6.3 the TH 
activity was significantly diminished (2,3), and may indicate rela-
tive inactivation of the enzyme. By lowering the pH of the assay 
mixture to 6QO, the activity of TH is increased severalfold compared 
to its activity at pH 6.5. This suggests that haloperidol produces 
activation of a relatively inh-ibited enzyme. It is recognized that 
one cannot conclusively state whether the hydrogen ion concentration 
is acting directly on the enzyme itself or whether another component 
of the assay system is affected which may indirectly influence the 
apparent enzyme activity. The haloperidol-induced activation of TH 
is relatively small compared to the in vitro maximally activated en-
zyme. The importance of this activation of TH through a decrease in 
15 
Km of the enzyme for the pteri di ne cofactor is not well unders tood at 
this time, but may, in fact, be much greater under physiological con-
dttions than under conditions employed in the in vitro assay. 
When phosphorylating conditions were employed at pH 6.5, similar 
kinetics were observed for TH from control and haloperidol-treated 
rats. The haloperidol-induced activation was no longer evident and 
the increased affinity of TH for the pteridine cofactor was reversed 
i.e., the Km returned to the control value (Fig. 1). For control TH, 
at pH 6.5, activation due to phosphorylation was accomplished by a 
change in Vmax only. In contrast, with phosphorylating conditions at 
the same pH, the kinetics of the enzyme from haloperidol-treated rats 
showed an increase in Km for the cofactor in addition to an increase 
in Vmax, to values similar to those observed for the phosphorylated 
enzyme from control rats. The marked difference in the kinetics of 
TH from haloperidol-treated rats on the one hand and TH from control 
and haloperidol-treated rats a~sayed under phosphorylating conditions, 
on the other, does not support the argument that haloperidol is pro-
ducing its effect through phosphorylation of TH. In fact, it sug-
gests that other mechanisms may be involved. 
The effect of pH on the ki netics of the control and contro 1-
phosphorylated enzyme with respect to the pteridine cofactor was then 
assessed by varying the pH of the assay mixture. The Vmax of control 
TH decreased markedly with increasing pH values, which is consistent 
with the narrow pH optimum of the enzyme (2); but the affinity of TH 
for the cofactor did not change significantly (Fig. 2a). An in-
crease in Vmax without a change in Km of the enzyme may reflect the 
16 
conversion of inactive enzyme molecules to catalytically active com-
ponents (8). 
When the kinetics of TH are compared in control or phosphoryla-
ting conditions at varying pH values, some interesting observations 
emerge. Whereas the Vmax of the control enzyme decreases dramatically 
with increasing pH, the Vmax of phosphorylated enzyme is not markedly 
altered by a change in pH but remains relatively high (Table 1). In 
contrast, the Km for cofactor of the control enzyme did not change 
significantly, but the Km of the phosphorylated TH increased two-
fold by increasing the pH from 6.0 to 6.5. 
The significance of these findings may be better appreciated if 
one considers that pH and phosphorylation, in addition to other fac-
tors such as nerve stimulation (9,17) inhibition by dopamine and nor-
epinephrine and anions (18,19), may be influencing TH activity under 
physiological conditions. Thus tyrosine hydroxylase may exhibit a 
great deal of flexibility with multiple mechanisms for modulation of 
catecholamine synthesis rates in response to a variety of complex con-
ditions which may be operating on the enzyme in vivo. 
Finally, conflicting reports have appeared concerning activation 
of TH with phosphorylation. In some cases a decrease in Km (4-7) 
has been reported while in others activation is manifested by a 
change in Vmax (8,10). Our observations may help resolve some of 
the controversy in the literature concerning the effects of cAMP on 
the kinetics of TH with respect to the pteridine cofactor. 
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EFFECTS OF METHAMPHETAMINE ON KINETIC CHARACTERISTICS 
OF NEOSTRIATAL TYROSINE HYDROXYLASE 
Introduction 
It has been reported previously from our laboratory that meth-
amphetamine in large doses depresses tyrosine hydroxylase (TH) in the 
corpus striatum (1,2) and in the substantia nigra (3). This decrease 
in en~e activity was prevented by concomitant administration of 
neuroleptic agents (2). The mechanism(s) by which methamphetamine 
depresses neostriata1 TH activity has not been elucidated. Such a 
depression of enzyme activity could be attributed to several factors 
such as a decrease in affinity of the enzyme for the cofactor or sub-
strate, activation of inhibitors, conversion of active components into 
inactive molecules, or to a decrease in the amount of enzyme present. 
The affinity for the pteridine cofactor of neostriatal TH is increased 
by a number of factors, including neuroleptic agents (4), phosphoryla-
tion and gel filtration (5), and polyanions (6). 
In this study, the kinetic characteristics of rat neostriatal 
tyrosine hydroxylase were examined after chronic treatment of rats 
with methamphetamine. The effects of employing a phosphorylating 
system in vitro on the kinetics of the enzyme were also explored. The 
results suggest that the decrease in TH activity cannot be attributed 
to a change in Km for the cofactor or substrate but, rather, to a de-
crease in the maximal velocity. 
21 
Methods 
Male Sprague-Dawley rats weighing 150-250 gm were housed three 
per cage in a temperature-controlled room (26°C) with a 12-hr light-
dark cycle. Food and water were offered ad libitum. 
Rats were injected every 6 hr with methamphetamine (15 mg/kg, 
s.c.) and were sacrificed by decapitation at varying intervals after 
initiating treatment. Rat neostriata were removed, placed on dry ice, 
and assayed within 24 hr. All steps for preparing the enzyme were 
performed at 0-5°C. TH activity was determined by the method of 
Nagatsu et a1. (7). The neostriata were homogenized in 0.8 m1 of 
0.2 M sodium acetate, pH 6.0, containing 0.2% Triton X-100 and were 
centrifuged at 27,000 xg for 15 min. at 4°Co The supernatants were 
assayed in a 100-~1 incubation medium containing 1 mM of ferrous am-
monium sulfate, 100 mM of mercaptoethanol, 0.2 M of sodium acetate, 
pH 6.0, 0.1 mM of tyrosine, 0.5 ~Ci of purified 3,5-ditritiotyrosine, 
and varying concentrations of 2-amino-4-hydroxy-6,7-dimethyltetrahy-
dropterin (DMPH4, Aldrich) or 2-amino-4-hydroxY-6-methy1tetrahydrop-
terin (6MPH4~ Calbiochem). 
When phosphorylating conditions were employed, the final con-
centration of the following components were 12.5 mM of magnesium 
acetate, 12.5 mM of sodium fluoride, 0.5 mM of theophylline, 75 ~M of 
EGTA, 312.5 ~M of ATP, .and 62.5 ~M of 31 , 51 ,-cAMP (8). In deter-
mining the kinetic constants with respect to tyrosine, concentrations 
of 0.02 to 0.1 mM were used with 6MPH4 (0.2 mM) or DMPH4 (2mM). 
The incubation was carried out at 37°C for 15 min. and terminated 
by the addition of 100 ~l of 10% trichloroacetic acid. The acidified 
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incubation medium was then placed on a 0.5 x 2.0 cm Dowex 50-H+ column 
and washed with 1.8 ml of distilled water. After the addition of 15 
ml of scintillation fluid, which contained 7.6 9 of 2,4 diphenyloxa-
zole in 1 liter of toluene-Triton X-100 (2:1), the radioactivity of 
the tritiated water produced was counted in a Packard liquid scintil-
lation counter. 
Results 
The neostriatal TH activity in rats treated with repeated doses 
of methamphetamine is reported in Figure lA. Double-reciprocal plots 
were obtained at various concentrations of the cofactor, DMPH 4 , 
against the initial velocity of tyrosine oxidized. Methamphetamine 
did not significantly change the apparent Km for cofactor, but it de-
creased the apparent Vmax of the enzyme from 2730 ± 272 to 1218 ± 387 
nmoles tyrosine oxidized/gm tissue/hr. The possible alteration by 
methamphetamine of the affinity of the enzyme for its substrate was 
also determined. Kinetic properties of neostriatal TH from normal 
rats and from those receiving methamphetamine are compared in Table 1. 
Enzyme activity was measured in the presence of either DMPH 4 (2 mM) 
or 6MPH4 (0.2 mM). Treatment of rats with methamphetamine did not 
significantly alter the apparent Km of TH for the substrate, tyrosine. 
The apparent Vmax was decreased to 47% of control when 6MPH4 was used 
as cofactor and 37% of control when DMPH4 was used as cofactor. This 
decrease is similar to the depression of enzyme activity observed in 
Figure lA. 
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At optimal pH conditions, phosphorylation of TH increases the af-
finity of the enzyme for the cofactor, while the initial velocity of 
the enzyme is unaltered (5,9). The influence of methamphetamine on 
the kinetic characteristics of neostriatal TH when an in vitro phos-
phorylating system was present in the incubation medium is shown in 
Figure lB. The apparent Km was decreased to the same degree, both in 
the neostriatum from methamphetamine-treated rats as well as from the 
saline control rats. The apparent Vmax was depressed by methamphet-
amine to the same extent when the phosphorylating system was present 
or absent. 
We have previously reported (3) that the neostriata1 dopamine 
levels were elevated within 6 hrs. after the initial dose of metham-
phetamine. The possibility that the drug in the initial stages of 
treatment was changing the Km of the enzyme for cofactor and, thus, 
increasing the synthesis of dopamine, was explored. The data pre-
sented in Table 2 indicate that there was no significant change in 
the apparent Km during the 36-hr. period when the Km and Vmax were 
monitored, while a gradual decrease in Vmax was observed over the 
same period of time. 
Discussion 
Neostriata1 TH activity is depressed by large, repeated doses of 
methamphetamine (1,2,3,10). This depression of enzyme activity could 
theoretically be attributed to an altered affinity of the enzyme for 
the cofactor or substrate or to a decreased Vmax. When the enzyme 
activity was measured with varying concentrations of cofactor, the 
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Fig. 1 Effect of methamphetamine on kinetics of neostriatal tyro-
sine hydroxylase. Double-reciprocol plots of initial velocity of 
tyrosine hydroxylase against various concentrations of either DMPH 4 
or 6MPH 4 in the presence of tyrosine (0.1 mM). The values shown are 
means of separate determinations on five different groups of rats. 
Fig. 1B also shows the effect of phosphorylating conditions on the 
kinetic properties of tyrosine hydroxylase. The conditions for 
phosphorylation experiments are described in the text. The velo-
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Table 1 
Kinetic Properties of Neostriata1 Tyrosine Hydroxylase 
in Rats Receiving Methamphetamine 
Km for Tyros; ne (mM) 
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Cofa'ctor Control METH Control METH 
DMPH 4 
6MPH4 
(2 mM) 0.10 ± 0.005 0.085 ± 0.008 3167 ± 769 1501 ± 168 
(002 mM) O.022± 0.002 0.023 ± 0.005 1547 ± 43 569 ± 37 
Methamphetamine (15 mg/kg, s.c.) was administered every 
6 hrs for 30 hrs and animals were sacrificed 35 hr after the 
first injection. The values given are means and standard 
error of the mean for 4 or more rats whose neostriata were 
analyzed separately. Enzyme activity was measured in the pre-
sence of either DMPH4 or 6MPH 4• Kinetic constants with re-
spect to tyrosine were determined using tyrosine concentra- . 
tions of. 0.02 to 0.1 mM. The velocities are expressed in 
nmoles of tyrosine oxidized/gm/hr. 
Table 2 
Time Response of.Methamphetamine on Kinetics 
of Rat Neostriatal Tyrosine Hydroxylase 
Hours of 
Methamphetamine 0 2 4 6 9 12 24 36 
Treatment 
Km Dt~PH4 (nM) 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1025 
Vmax 3125 3225 2941 2985 2439 2381 1219 1266 
The figures depict a representative experiment wherein 
the Km for DMPH4 and the Vmax were monitored for increasing 
periods of time after methamphetamine treatment. One dose of 
methamphetamine (15 mg/kg, s.c.) was administered in animals 
sacrificed at 2, 4 and 6 hrs, while two doses were administered 
to animals sacrificed 9 and 12 hrs. Animals sacrificed at 24 
and 35 hrs received four and five doses of methamphetamine 
respectively. Vmax is expressed in nmo1es tyrosine oxidized/ 
gm tissue/hr. 
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apparent Km for the cofactor was not affected (~ig. 1). In addition, 
the affinity of TH for the substrate did not change with treatment of 
rats with methamphetamine (Table 1). A· similar depression in the 
Vmax of TH was observed when both cofactor and substrate concentra-
tions were varied in normal and methamphetamine-treated rats. 
Lovenberg et al. (8) found that addition of a phosphorylating 
system in vitro to the assay medium reduced the apparent Km for co-
factor of solubilized TH from rat neostriata. When an in vitro phos-
phorylating system was added to the assay medium for the measurement 
of neostriatal TH activity from normal and methamphetamine-treated 
rats, the apparent Km was altered by phosphorylation, but methamphet-
amine had no effect on the apparent Km for the cofactor. The apparent 
Vmax was altered to the same degree by methamphetamine with or with-
out a phosphorylating system in the incubation medium (Fig. lB). 
The exact mechanism by which metharnphetamine is causing a de-
crease in TH activity cannot be conclusively defined at this time. 
Several mechanisms may provide. an explanation for the decrease in TH 
activity following treatment of rats with methamphetamine. Examples 
include our hypothesis proposed earlier (2), by which methamphetamine-
released dopamine in the neostriatum results in an intense activation 
of the striatonigral neuronal feedback loop to the substantia nigra 
which would cause a d~creased synthesis of TH in the cell bodies of 
the nigrostriatal pathway located in the substantia nigra. However, 
results obtained recently (11) in our laboratory with lesiOn studies, 
in addition to electrophysio10gical data reported by Groves et al. 
(12) and Bunney et al. (13), suggest that the initial site of action 
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of methamphetamine may be the release of dopamine from the dendrites 
of dopaminergic neurons in the nigra. The released dopamine would 
then act on autoreceptors located on cell bodies or on dendrites in 
the nigra to depress the firing rate of the dopaminergic cells 
which would result in a decrease in neostriatal TH activity 18-36 hrs 
later, as we previously observed (3). Another mechanism that may ex-
plain the data reported in this paper involves the activation of pre-
synaptic receptors. Carlsson and associates (14) suggested that 
dopamine activates "autoreceptors ll on the nerve terminals, which de-
creases TH activity in the nerve terminal. Presumably, the neuro-
leptic agents would prevent this effect by blocking the presynaptic 
"autoreceptors. II 
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PART FOUR 
PROPRANOLOL DIFFERENTIALLY BLOCKS THE METHAMPHETAMINE-INDUCED 
DEPRESSION OF TRYPTOPHAN HYDROXYLASE: IMPLICATIONS OF 
USE IN SCHIZOPHRENIA 
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In recent years, large doses of propranolol have been reported 
to be beneficial in the treatment of schizophrenia (1). In addition 
to their membrane stabilizing and a-blocking activity, recent evidence 
indicates that propranolol and related a-blockers have 5-hydroxytrypt-
amine (5HT) receptor antagonist activity. It has been shown that 
propranolol has high affinity for 5HT binding sites (2), blocks 5HT-
induced hyperactivity in rats (3), and antagonizes the action of 5HT 
in the superior cervical ganglion of cats (4). High doses of meth-
amphetamine or amphetamine can produce symptoms similar to paranoid 
schizophrenia in humans (5). In animals, methamphetamine or amphet-
amine produces a stereotypic behavior which is thought by some to be 
an animal correlate of human schizophrenia (6). Acute (7) and 
chronic (8) administration of methamphetamine produces large de-
creases in the activity of tryptophan hydroxylase (TPH), the rate-
limiting enzyme in the biosynthesis of 5HT (9), in serotonergic 
nerve terminal regions of the rat brain. In addition, methamphetamine 
(10) and amphetamine (11) decrease the levels of brain 5HT and 5-
hydroxyindoleacetic acid (5HIAA). Furthermore, clinical reports in-
dicate that increased urinary excretion of 5HIAA by some schizophre-
nic patients, is reduced upon treatment with propranolol (12). Thus 
it has been proposed that a biochemical aberration of the serotonergic 
system may be involved in schizophrenia (13). In this study we re-
port that propranolol blocks the methamphetamine-induced depression 
of TPH in a regionally selective manner. 
Male Sprague-Dawley rats (Sasco. Omaha) weighing 200 to 300 g 
were used in these experiments. Rats were administered either meth-
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amphetamine (10 mg/kg, s.c.), d,l-propranolol (40 mg/kg, i.p.), hal-
operidol (0.5 mg/kg, i.p.) or methamphetamine with either of the two 
antagonists concurrently. Control rats were injected with saline. 
Rats were sacrificed by decapitation 3 hours after drug injection. 
Experiments were designed so that all rats were sacrificed between 
11 a.m. and 2 porn. to avoid any significant variation in TPH activity 
due to diurnal rhythm. After decapitation, rat brains were rapidly 
removed and the following regions dissected on ice: nucleus accum-
bens, olfactory tubercle, neostriatum, hypothalamus, cerebral cortex, 
hippocampus, spinal cord, and raphe nuclei. All brain tissues were 
stored at -70'o C until assayed. Tryptophan hydroxylase activity was 
measured by a 14C02 trapping method (14)~ as described by Hotchkiss 
et a1. (8). 
The basal level of activity of tryptophan hydroxylase in the re-
gions studied is shown in Table 1. TPH activity varied from one re-
gion to another. The cell body region, raphe nuclei, had enzyme ac-
tivity that was several-fold higher than the terminal regions. Among 
the terminal regions, hypothalamus, hippocampus and spinal cord had 
much higher basal enzyme activity than the other regions. Following 
a single dose of methamphetamine (10 mg/kg), TPH activity was markedly 
depressed in all serotonergic nerve terminal regions assayed (Table 1). 
Reduction in enzyme activity varied from one region to another; TPH 
activities in the cortex, hippocampus, olfactory tubercle, and spinal 
cord were reduced to less than half of control values. However, en-
zyme activity in the serotonergic nerve ce]l bodies in the raphe 
nuclei were not affected (8). Concurrent administration of pro-
Table 1. Effect of drug treatment on tryptophan hydroxylase activity. Values 
for nucleus accumbens and olfactory tubercle expressed in nmo1es tryptophan oxi~ 
dized/mg protein/hr. (mean ± S.E.M.). All other values are in nmo1es/gram tis-
sue weight/hr. Values in brackets are percent of control. 
meth-
amphetarni ne methamphetamine 
control propranolol meth ... + + 
amphetamine propranolol ha loped do 1 
N. Accumtens 0.22 ± 0.01 0.241: 0.02a 0.12±0.02 b 0.191: 0.02a ,d O.14tO.Ol b •c 
(1 O!1%) (51%) (86%) (61)%) 
O. Tubercle 0.24 ± 0.02 .0.26:1: 0.01 a 0.08 ± 0.02 b 0.181: 0.02b•d 0.12 i 0.02b •d 
(106% ) (33%) ( 75~'~) (50%) 
tlecstriatum 15.0 ± 1.2 18.0 :f. LOa 9.0 ± 0.9 b 13.8 ± 2.03 ,d 9.4 ± 1.5b•c 
(120~~ ) (60%) (92%) (63%) 
Hypothalamus 55.0 :t: 5.7 75.0 ~ 8.0a 35.0 ± 2.B b 54.0 ± 4.0a •d 37.4 ± 2.9b •c 
(136:t ) (64~~) (98X) (68%) 
C. Cort~x 19.0 ± 0.9 21.5.t 0.8a 8.9 ! 1.4 b 12.4 ± 1.l b •d 9.3 ± 1.ab•c 
(lO8%) (45%) (62:0 (47%) 
Hippocampus 36.0 ± 1.4 34.0 ± 1.4a b 19.8 ± 1.6btd 21.0 ± 1.4b •d 14.0 ± 1.7 
(94~{, ) (39%) (55%) (S8%) 
Spinal Cord 30.7 ± 1.3 23.0 ± 1.Ba b 16.6 ± 3.0b •C 20.6 ± 2.2b •d 13.9 ± 1.9 
(75%) (45%) (54%) (67:t) 
Raphe 630 ± 62 675 ± 63a 508 ± 64a 517 ± 39a 
(107%) (81%) (82%) 
a not significantly different from control, p~O.05. 
b significantly different from control, p<0.05. 
C not S1 gni ficantly di fferent from methamphetami ne tteatment. p>0.05. 




pranolol (40 mg/kg, i.p.) produced differential regional blockade of 
TPH depression induced by methamphetamine. Depression of enzyme 
act1vities in the mesolimbic (nucleus accumbens and olfactory tuber-
cle) areas, neostriatum and hypothalamus was almost completely 
blocked by propranolol, whereas the activities in other regions were 
still markedly depressed. Propranolol alone had no significant ef-
fect on TPH activity, although a trend toward an increase was ob-
served, especially in the hypothalamus (Table 1). To compare the 
effects of propranolol with a more commonly used antipsychotic drug, 
haloperidol (0.5 mg/kg, i.p.) was given concurrently with methamphet-
amineo Haloperidol produced partial blockade of the methamphetamine-
induced depression of TPH in olfactory tubercle, hippocampus and 
spinal cord and no significant blockade in all other regions (Table 
1).. Haloperidol a,lone had no significant effect on enzyme activ-
1 ties. 
These data indicate that propranolol produces significant block-
ade of the methamphetamine-induced depression of TPHo It is inter-
esting to note that the extent of the blockade varies from one sero-
tonergic terminal region to another. Furthermore, in the mesolimbic 
areas. neostriatum and hypothalamus, regions that are commonly im-
plicated in schizophrenia (15), propranolol almost completely pre-
vents the depression in TPH activity. In contrast, only partial 
protection against enzyme depression is observed in the hippocampus 
and cortex and no effect was found in spinal cord. However, unlike 
propranolol. the antipsychotic drug haloperidol in the dose used, 
did not significantly protect against enzyme depression in most re-
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gions. Unlike the long latency of the antipsychotic drugs to pro-
duce their effect, propranolol provides rapid relief from clinical 
symptoms of schizophrenia (1). Thus, the acute effects of propranolol 
on TPH activity are compatible with its clinical effects. 
High doses of propranolol were used in this study. Clinically, 
there is wide variation in the dosage of propranolol that is ef-
fective in schizophrenic patients, but doses of 3000 mg/day are not 
uncommon, and doses of more than 5000 mg/day have been reported (1). 
In fact, low doses do not appear to be effective in relieving schizo-
phrenic symptoms (16). 
We have' previously reported (17) that methamphetamine produces a 
marked decrease in tyrosine hydroxylase activity only after chronic 
treatment. In contrast, a single injection of methamphetamine causes 
a marked decrease in TPH activit Yo Thus, it appears that the sero-
tonergic system is more vul~erable to the action of methamphetamine. 
Furthermore, several reports (18) have demonstrated an interaction 
between the dopaminergic and serotonergic systems. Considering the 
complexity of the schizophrenic syndrome, this difference may help 
explain the clinical effectiveness of drugs such as propranolol and 
haloperidol which have diverse mechanisms, in the treatment of 
schizophrenia. 
Our data complement previous reports (12) which suggest an in-
volvement of the serotonergic system in schizophrenia. The present 
results demonstrate for the first time that propranolol blocks the 
methamphetamine-induced depression of TPH in a regionally selective 
manner. These findings may provide a biochemical rationale for the 
efficacy of propranolol in schizophrenia. In addition, these re-
s'ults emphasize the regional differences in sensitivity of seroto-
nergic nerve terminal regions to drug treatment and, hence, the 
potential importance of these differences to the response by the 
central nervous system, in the etiology of schizophrenia. 
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